Literature DB >> 6480004

Inherent limitations of the yellow card system for the detection of unsuspected adverse drug reactions.

I Crombie.   

Abstract

The number of cases of an adverse reaction which could be seen by individual doctors was investigated taking realistic values for the frequency of drug prescribing and a range of frequencies of adverse drug reactions. The results indicated that, for almost all drugs, general practitioners (GPs) will seldom see other than single cases of an adverse reaction. It is argued that doctors will be unlikely to recognize an adverse reaction from a single case (unless it presented with some striking clinical features) so that potential new adverse reactions will rarely be reported by GPs under the Yellow Card scheme. A similar analysis for hospital doctors indicated that clinicians working in some specialties, may have a greater chance of seeing more than one case of an adverse reaction. A review of the identification of several important adverse reactions revealed that all the reports from British doctors were submitted by clinicians with hospital appointments. This study suggests that the major part of the operation of the Yellow Card system will contribute little to the identification of adverse reactions and that its organization and activities need to be reassessed. A modified system designed to encourage reporting by hospital clinicians could be of greater value.

Mesh:

Year:  1984        PMID: 6480004     DOI: 10.1177/096032718400300402

Source DB:  PubMed          Journal:  Hum Toxicol        ISSN: 0144-5952


  5 in total

Review 1.  Antiepileptic drugs and pregnancy outcomes.

Authors:  Bogdan J Wlodarczyk; Ana M Palacios; Timothy M George; Richard H Finnell
Journal:  Am J Med Genet A       Date:  2012-06-18       Impact factor: 2.802

Review 2.  Teratogenic effects of antiepileptic drugs.

Authors:  Denise S Hill; Bogdan J Wlodarczyk; Ana M Palacios; Richard H Finnell
Journal:  Expert Rev Neurother       Date:  2010-06       Impact factor: 4.618

3.  Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.

Authors:  Guillaume L Martin; Julien Jouganous; Romain Savidan; Axel Bellec; Clément Goehrs; Mehdi Benkebil; Ghada Miremont; Joëlle Micallef; Francesco Salvo; Antoine Pariente; Louis Létinier
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

Review 4.  Reported paediatric adverse drug reactions in the UK 2000-2009.

Authors:  Daniel B Hawcutt; Pramod Mainie; Andrew Riordan; Rosalind L Smyth; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

5.  Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting.

Authors:  Saima Afzal; Syed Tabish Razi Zaidi; Hamid A Merchant; Zaheer-Ud-Din Babar; Syed Shahzad Hasan
Journal:  J Thromb Thrombolysis       Date:  2021-03-05       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.